exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Todays Updates

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD David Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

How Candida Moves From Mouth to Gut in IBD, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Todays Updates

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD David Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

How Candida Moves From Mouth to Gut in IBD, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Latest News

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

News All Time

NeuroVoices: Kamalini Galvelis, MS, on Why Diverse Cohorts Matter in Replicating a GBA1 Intronic Risk Variant Isabella Ciccone, MPH, Kamalini Galvelis, MS

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Clinical Forum Highlights Shifting Paradigm in NF1 Plexiform Neurofibroma Care Marco Meglio

At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows Marco Meglio

A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.

Givinostat Data Point to Delayed Loss of Ambulation, Preserved Muscle Tissue in DMD Isabella Ciccone, MPH

An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.

NeurologyLive® Brain Games: October 4, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype Marco Meglio

New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Recommended News For You

Why preventive mastectomy isn't offered to everyone at risk

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Short-course radiation matches standard therapy for endometrial cancer

Adult overdose deaths on the rise

Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT

Patients face high out-of-pocket costs after incident cancer diagnosis

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

Recommended Articles For You

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities 

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms 

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology 

Emerging Therapies Using Immune-Reshaping Tumor Microenvironment Technologies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Future of Lab-Developed Tests Still Taking Shape

2.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

3.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

4.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

5.

Q&A: Breast cancer facts that could save lives

1.

Patient-Centric Approaches in Hematology: Integrating Individualized Care into Modern Clinical Practice

2.

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology

3.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

4.

Clinical Pharmacology of Erythropoiesis-Stimulating Pathway Modulators

5.

Innovative Pathways in Oncology Across Clinical Settings

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

2.

Early warning sings of camcer that need medical attention

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

4.

Understanding Common Causes of Abnormal Blood Counts

5.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot